Upgrade to SI Premium - Free Trial

TD Cowen Downgrades Sage Therapeutics (SAGE) to Hold

July 30, 2024 5:29 AM
TD Cowen analyst Ritu Baral downgraded Sage Therapeutics (NASDAQ: SAGE) from Buy to Hold with a price target of $10.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades

Next Articles